(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Fostamatinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms OSKIRA-X
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 06 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Jun 2012 Additional trial locations (Colombia, Turkey) identified as reported by EudraCT.